| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 23 | 2024 | 3021 | 1.350 |
Why?
|
| Neoadjuvant Therapy | 8 | 2024 | 376 | 0.640 |
Why?
|
| Neoplasm Recurrence, Local | 9 | 2024 | 1352 | 0.490 |
Why?
|
| Mastectomy | 4 | 2015 | 246 | 0.390 |
Why?
|
| Receptor, ErbB-2 | 3 | 2023 | 247 | 0.380 |
Why?
|
| Carcinoma, Ductal, Breast | 3 | 2022 | 160 | 0.380 |
Why?
|
| Hyperparathyroidism | 3 | 2002 | 67 | 0.370 |
Why?
|
| Mastectomy, Segmental | 3 | 2021 | 101 | 0.330 |
Why?
|
| Parathyroid Neoplasms | 2 | 2002 | 60 | 0.330 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2024 | 2506 | 0.300 |
Why?
|
| Adenoma | 2 | 2002 | 250 | 0.290 |
Why?
|
| Neoplasm Staging | 8 | 2021 | 2000 | 0.270 |
Why?
|
| Aromatase Inhibitors | 1 | 2006 | 29 | 0.270 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 2 | 2022 | 117 | 0.250 |
Why?
|
| Sentinel Lymph Node Biopsy | 2 | 2017 | 73 | 0.250 |
Why?
|
| Lymphadenopathy | 1 | 2024 | 20 | 0.230 |
Why?
|
| Middle Aged | 24 | 2024 | 26132 | 0.220 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2024 | 98 | 0.220 |
Why?
|
| Female | 33 | 2024 | 46571 | 0.210 |
Why?
|
| Carcinoma, Lobular | 2 | 2015 | 81 | 0.200 |
Why?
|
| Mammaplasty | 3 | 2013 | 110 | 0.200 |
Why?
|
| Technetium Tc 99m Sestamibi | 1 | 2002 | 15 | 0.200 |
Why?
|
| Lymph Nodes | 2 | 2017 | 550 | 0.200 |
Why?
|
| Reoperation | 5 | 2013 | 604 | 0.200 |
Why?
|
| Parathyroidectomy | 1 | 2002 | 80 | 0.190 |
Why?
|
| Parathyroid Hormone | 1 | 2002 | 220 | 0.190 |
Why?
|
| Adenocarcinoma | 5 | 2003 | 1185 | 0.180 |
Why?
|
| Radiopharmaceuticals | 1 | 2002 | 197 | 0.180 |
Why?
|
| Combined Modality Therapy | 10 | 2023 | 1704 | 0.180 |
Why?
|
| Intestinal Neoplasms | 1 | 2001 | 68 | 0.170 |
Why?
|
| Postoperative Complications | 4 | 2013 | 2313 | 0.170 |
Why?
|
| Adult | 20 | 2024 | 26810 | 0.170 |
Why?
|
| Body Weight | 1 | 2021 | 453 | 0.170 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2024 | 476 | 0.160 |
Why?
|
| Aged | 16 | 2024 | 19240 | 0.160 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2020 | 173 | 0.160 |
Why?
|
| Humans | 37 | 2024 | 89924 | 0.160 |
Why?
|
| Prognosis | 7 | 2024 | 3796 | 0.150 |
Why?
|
| Age Factors | 1 | 2023 | 1880 | 0.150 |
Why?
|
| Gastrinoma | 1 | 1996 | 2 | 0.140 |
Why?
|
| Zollinger-Ellison Syndrome | 1 | 1996 | 10 | 0.140 |
Why?
|
| BRCA1 Protein | 1 | 2018 | 205 | 0.140 |
Why?
|
| Urinary Catheterization | 1 | 2016 | 36 | 0.130 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2024 | 3470 | 0.130 |
Why?
|
| Radiotherapy | 3 | 2013 | 332 | 0.120 |
Why?
|
| Ultrasonography | 1 | 2017 | 720 | 0.120 |
Why?
|
| Aged, 80 and over | 9 | 2021 | 6780 | 0.120 |
Why?
|
| Biopsy | 3 | 2018 | 1184 | 0.120 |
Why?
|
| Survival Rate | 4 | 2024 | 1898 | 0.120 |
Why?
|
| Early Detection of Cancer | 1 | 2018 | 422 | 0.120 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 952 | 0.120 |
Why?
|
| Crohn Disease | 1 | 2001 | 764 | 0.110 |
Why?
|
| Phyllodes Tumor | 1 | 2013 | 7 | 0.110 |
Why?
|
| Follow-Up Studies | 5 | 2024 | 3680 | 0.110 |
Why?
|
| Mass Screening | 1 | 2018 | 646 | 0.110 |
Why?
|
| Esophageal Neoplasms | 4 | 2003 | 332 | 0.100 |
Why?
|
| Lymphokines | 3 | 2002 | 75 | 0.100 |
Why?
|
| Retrospective Studies | 8 | 2022 | 9203 | 0.100 |
Why?
|
| Neoplasm, Residual | 2 | 2023 | 181 | 0.100 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2016 | 539 | 0.090 |
Why?
|
| Endothelial Growth Factors | 2 | 2002 | 55 | 0.090 |
Why?
|
| Pancreatic Neoplasms | 1 | 1996 | 684 | 0.090 |
Why?
|
| Proportional Hazards Models | 3 | 2021 | 848 | 0.090 |
Why?
|
| Clinical Competence | 1 | 2016 | 795 | 0.090 |
Why?
|
| Paclitaxel | 2 | 2019 | 474 | 0.090 |
Why?
|
| Breast | 2 | 2023 | 292 | 0.090 |
Why?
|
| Genetic Therapy | 2 | 2003 | 372 | 0.090 |
Why?
|
| Mammography | 3 | 2021 | 475 | 0.080 |
Why?
|
| Peptide Fragments | 2 | 2003 | 463 | 0.080 |
Why?
|
| Time Factors | 5 | 2013 | 5357 | 0.080 |
Why?
|
| Neoplasm Proteins | 2 | 2002 | 538 | 0.070 |
Why?
|
| Endothelium, Vascular | 4 | 2002 | 435 | 0.070 |
Why?
|
| Cohort Studies | 2 | 2023 | 2887 | 0.070 |
Why?
|
| Prospective Studies | 3 | 2021 | 4325 | 0.070 |
Why?
|
| Tumor Cells, Cultured | 6 | 2005 | 1048 | 0.070 |
Why?
|
| Neoplasm Invasiveness | 2 | 2019 | 569 | 0.060 |
Why?
|
| Tamoxifen | 1 | 2006 | 168 | 0.060 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2002 | 1283 | 0.060 |
Why?
|
| Glycine | 1 | 2005 | 95 | 0.060 |
Why?
|
| Cyclophosphamide | 1 | 2005 | 301 | 0.060 |
Why?
|
| Adjuvants, Immunologic | 1 | 2005 | 169 | 0.060 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2003 | 700 | 0.060 |
Why?
|
| Radiation, Ionizing | 2 | 2000 | 123 | 0.050 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2005 | 274 | 0.050 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2015 | 290 | 0.050 |
Why?
|
| Adaptive Clinical Trials as Topic | 1 | 2022 | 6 | 0.050 |
Why?
|
| Mucin-1 | 1 | 2003 | 44 | 0.050 |
Why?
|
| Mice, Nude | 5 | 2003 | 816 | 0.050 |
Why?
|
| Intraoperative Period | 1 | 2002 | 91 | 0.050 |
Why?
|
| Adolescent | 4 | 2015 | 9339 | 0.050 |
Why?
|
| Collagen | 2 | 2000 | 294 | 0.050 |
Why?
|
| Antineoplastic Agents | 2 | 2005 | 2331 | 0.050 |
Why?
|
| Young Adult | 3 | 2022 | 6408 | 0.050 |
Why?
|
| Body Weights and Measures | 1 | 2021 | 27 | 0.050 |
Why?
|
| Coumarins | 1 | 2000 | 13 | 0.050 |
Why?
|
| Immediate-Early Proteins | 1 | 2002 | 164 | 0.050 |
Why?
|
| Neoplasm Transplantation | 4 | 2005 | 397 | 0.050 |
Why?
|
| Monitoring, Physiologic | 1 | 2002 | 265 | 0.050 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2005 | 1098 | 0.040 |
Why?
|
| Male | 6 | 2016 | 42657 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2021 | 374 | 0.040 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 1999 | 97 | 0.040 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2019 | 31 | 0.040 |
Why?
|
| Receptors, Steroid | 1 | 2019 | 42 | 0.040 |
Why?
|
| Trastuzumab | 1 | 2019 | 73 | 0.040 |
Why?
|
| Doxorubicin | 1 | 2019 | 293 | 0.040 |
Why?
|
| Neoplasms, Experimental | 1 | 1999 | 269 | 0.040 |
Why?
|
| Stress, Physiological | 1 | 1999 | 232 | 0.040 |
Why?
|
| Body Mass Index | 1 | 2021 | 776 | 0.040 |
Why?
|
| Mice | 8 | 2005 | 11851 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2019 | 341 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2021 | 1497 | 0.040 |
Why?
|
| Axilla | 1 | 2017 | 103 | 0.040 |
Why?
|
| Comorbidity | 1 | 2021 | 953 | 0.040 |
Why?
|
| Neovascularization, Pathologic | 1 | 1999 | 354 | 0.040 |
Why?
|
| Anorexia | 1 | 1997 | 28 | 0.030 |
Why?
|
| Transplantation, Heterologous | 3 | 2003 | 368 | 0.030 |
Why?
|
| ROC Curve | 1 | 2019 | 778 | 0.030 |
Why?
|
| Thyroidectomy | 1 | 1997 | 171 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 2 | 2002 | 1394 | 0.030 |
Why?
|
| Decision Trees | 1 | 1996 | 60 | 0.030 |
Why?
|
| Urinary Catheters | 1 | 2016 | 6 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2021 | 1864 | 0.030 |
Why?
|
| Registries | 1 | 2021 | 808 | 0.030 |
Why?
|
| DNA-Binding Proteins | 1 | 2002 | 1244 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 1729 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2017 | 495 | 0.030 |
Why?
|
| Healthcare Disparities | 1 | 2020 | 432 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 1997 | 261 | 0.030 |
Why?
|
| Neoplasms | 2 | 2000 | 3065 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2017 | 785 | 0.030 |
Why?
|
| Intraoperative Complications | 1 | 1996 | 185 | 0.030 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2019 | 586 | 0.030 |
Why?
|
| Protein Biosynthesis | 1 | 1997 | 389 | 0.030 |
Why?
|
| Adipose Tissue | 1 | 1997 | 262 | 0.030 |
Why?
|
| Preoperative Care | 1 | 1996 | 395 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2002 | 1665 | 0.030 |
Why?
|
| Surgical Procedures, Operative | 1 | 1996 | 206 | 0.030 |
Why?
|
| Education, Medical | 1 | 2016 | 243 | 0.030 |
Why?
|
| Cytokines | 1 | 1997 | 811 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 4 | 2000 | 3252 | 0.030 |
Why?
|
| Transcription, Genetic | 1 | 1997 | 1158 | 0.020 |
Why?
|
| Animals | 8 | 2005 | 27526 | 0.020 |
Why?
|
| Adenoviridae | 2 | 2003 | 349 | 0.020 |
Why?
|
| Inflammation | 1 | 1997 | 981 | 0.020 |
Why?
|
| Genetic Vectors | 2 | 2003 | 446 | 0.020 |
Why?
|
| Umbilical Veins | 2 | 2000 | 46 | 0.020 |
Why?
|
| Carcinoma, Lewis Lung | 2 | 2000 | 24 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factors | 2 | 2002 | 56 | 0.020 |
Why?
|
| Phosphatidylcholines | 1 | 1990 | 49 | 0.020 |
Why?
|
| Cells, Cultured | 3 | 2000 | 2887 | 0.020 |
Why?
|
| False Negative Reactions | 1 | 2010 | 63 | 0.020 |
Why?
|
| Radiation Tolerance | 2 | 2002 | 173 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 1990 | 315 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2018 | 2362 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 2 | 2003 | 961 | 0.020 |
Why?
|
| Gadolinium DTPA | 1 | 2010 | 256 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2002 | 405 | 0.020 |
Why?
|
| Recombinant Proteins | 2 | 2000 | 1008 | 0.020 |
Why?
|
| Mutation | 1 | 2018 | 4165 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2000 | 1929 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2010 | 1607 | 0.020 |
Why?
|
| Escherichia coli | 2 | 2000 | 607 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2010 | 2018 | 0.020 |
Why?
|
| Radiodermatitis | 1 | 2005 | 10 | 0.020 |
Why?
|
| Injections, Intraperitoneal | 1 | 2005 | 101 | 0.020 |
Why?
|
| Contrast Media | 1 | 2010 | 1084 | 0.020 |
Why?
|
| Mice, Inbred C3H | 1 | 2005 | 371 | 0.010 |
Why?
|
| Drug Synergism | 1 | 2005 | 307 | 0.010 |
Why?
|
| Apoptosis | 2 | 2002 | 1718 | 0.010 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2005 | 485 | 0.010 |
Why?
|
| Risk Factors | 1 | 2013 | 5554 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2005 | 983 | 0.010 |
Why?
|
| Wound Healing | 1 | 2005 | 361 | 0.010 |
Why?
|
| Luminescent Proteins | 1 | 2003 | 144 | 0.010 |
Why?
|
| Random Allocation | 1 | 2003 | 327 | 0.010 |
Why?
|
| Early Growth Response Protein 1 | 1 | 2002 | 57 | 0.010 |
Why?
|
| Green Fluorescent Proteins | 1 | 2003 | 309 | 0.010 |
Why?
|
| RNA, Messenger | 2 | 1999 | 2026 | 0.010 |
Why?
|
| Cell Line, Transformed | 1 | 2002 | 154 | 0.010 |
Why?
|
| Models, Animal | 1 | 2003 | 277 | 0.010 |
Why?
|
| Virus Replication | 1 | 2003 | 326 | 0.010 |
Why?
|
| Isocoumarins | 1 | 2000 | 7 | 0.010 |
Why?
|
| Collagen Type XVIII | 1 | 2000 | 4 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2002 | 226 | 0.010 |
Why?
|
| Endostatins | 1 | 2000 | 6 | 0.010 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2000 | 46 | 0.010 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2000 | 189 | 0.010 |
Why?
|
| Chicago | 1 | 2005 | 1431 | 0.010 |
Why?
|
| Pichia | 1 | 2000 | 29 | 0.010 |
Why?
|
| Laminin | 1 | 2000 | 89 | 0.010 |
Why?
|
| Drug Combinations | 1 | 2000 | 203 | 0.010 |
Why?
|
| Proteoglycans | 1 | 2000 | 123 | 0.010 |
Why?
|
| Microcirculation | 1 | 2000 | 105 | 0.010 |
Why?
|
| Cell Separation | 1 | 2000 | 199 | 0.010 |
Why?
|
| Tumor Stem Cell Assay | 1 | 1999 | 37 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 2000 | 645 | 0.010 |
Why?
|
| RNA, Neoplasm | 1 | 1999 | 88 | 0.010 |
Why?
|
| Cell Survival | 1 | 2002 | 983 | 0.010 |
Why?
|
| Culture Media, Conditioned | 1 | 1999 | 103 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2000 | 690 | 0.010 |
Why?
|
| Disease Progression | 1 | 2002 | 1469 | 0.010 |
Why?
|
| Ciliary Neurotrophic Factor | 1 | 1997 | 1 | 0.010 |
Why?
|
| Leukemia Inhibitory Factor | 1 | 1997 | 4 | 0.010 |
Why?
|
| Cell Movement | 1 | 2000 | 786 | 0.010 |
Why?
|
| Growth Inhibitors | 1 | 1997 | 41 | 0.010 |
Why?
|
| Glioblastoma | 1 | 1999 | 267 | 0.010 |
Why?
|
| Leptin | 1 | 1997 | 102 | 0.010 |
Why?
|
| Interleukin-4 | 1 | 1997 | 129 | 0.010 |
Why?
|
| Interleukins | 1 | 1997 | 132 | 0.010 |
Why?
|
| Interleukin-2 | 1 | 1997 | 241 | 0.010 |
Why?
|
| Interleukin-10 | 1 | 1997 | 155 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2000 | 1801 | 0.010 |
Why?
|
| Lipopolysaccharides | 1 | 1997 | 295 | 0.010 |
Why?
|
| Melanoma | 1 | 1999 | 471 | 0.010 |
Why?
|
| Recurrence | 1 | 1997 | 1145 | 0.010 |
Why?
|
| Kinetics | 1 | 1997 | 1534 | 0.010 |
Why?
|
| Nerve Tissue Proteins | 1 | 1997 | 511 | 0.010 |
Why?
|
| Proteins | 1 | 1997 | 786 | 0.010 |
Why?
|
| Chromatography, Thin Layer | 1 | 1990 | 32 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2002 | 3403 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2002 | 8270 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 1999 | 2369 | 0.000 |
Why?
|
| Diabetes Mellitus | 1 | 1990 | 744 | 0.000 |
Why?
|